I am left wondering if, like Teva before them, Celgene will soon be considered a bunch of bone-headed number crunchers.
Anyone can make mistakes, even large corporations. The biggest error is in assuming they always get it right.
Good to see you're starting to question your own assumptions...
But my view is pretty much that if Celgene is bargaining hard, MSB is bargaining harder.
Nothing to do with size, it's about strategy.
Ann: Appendix 4C - quarterly, page-48
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |